Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,138.81 USD
-7.94 (-0.69%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1,140.43 +1.62 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
REGN 1,138.81 -7.94(-0.69%)
Will REGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
Other News for REGN
JMP Securities healthcare analysts hold an analyst/industry conference call
Buy Rating Affirmed: Regeneron’s Growth Potential Anchored by Strong Pipeline and Market Performance
RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN)
Analyst Issues Sell Rating for Regeneron Amid Competitive Challenges and Limited Market Potential
IN BRIEF: Sanofi and Regeneron show Dupixent treats bullous pemphigoid